What Phare Bio does

Phare Bio is a nonprofit social venture founded in 2020 that applies generative AI and deep learning to discover novel classes of antibiotics, with the stated mission of addressing the global antimicrobial resistance (AMR) crisis. Its core product is AIBiotics, a generative AI discovery platform developed in partnership with the Collins Lab at MIT that screens 1000x more molecules at 5x speed and 100x greater success rate than traditional approaches, combining fragment-based screening with de novo compound generation. The platform has produced peer-reviewed results in Cell and Nature (2025), including two lead candidates (NG1 and DN1) demonstrating bactericidal efficacy against drug-resistant pathogens in mouse models, and is supported by an ARPA-H grant to design 15 new antibiotics as preclinical candidates.

The business model is a hybrid social venture that bifurcates funding sources by development stage. Donor and grant capital (TED's Audacious Project at founding, a $27 million ARPA-H award in September 2024, and Google.org's Generative AI Accelerator in 2025) funds preclinical discovery through the "valley of death" where most antibiotic programs fail. Once candidates are de-risked preclinically, Phare Bio advances them through strategic commercial partnerships — most notably with Basilea Pharmaceutica (announced December 2025), which includes success-based payments — or through company spin-outs intended to provide a sustainable clinical path to patients. The company does not sell products directly and pricing is not publicly disclosed; revenue mechanics are tied to grant inflows and contingent milestone payments rather than commercial sales.

Phare Bio serves global healthcare systems facing the AMR crisis and large pharmaceutical companies seeking to replenish depleted antibiotic pipelines, targeting urgent threats such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its GTM motion is enterprise partnership-led, leveraging the scientific credibility of the Collins Lab and a senior advisory bench drawn from GSK, Merck, Pfizer, Johnson & Johnson, and Evotec to secure co-development deals. The organization operates as a going concern with a small core team (1-10 employees per firmographics) supplemented by an extensive advisor network.

Name

Phare Bio

Legal name

Phare Bio Inc.

Website

https://pharebio.org

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

AI-enabled antibiotic drug discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF)

Keywords

• AI drug discovery
• Antibiotic discovery platform
• Antimicrobial resistance therapeutics
• Generative AI drug design
• Preclinical drug development

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Philanthropic/Grant Funding: Phare Bio operates as a nonprofit social venture funded primarily through grants and donations. The company addresses the 'valley of death' in preclinical development with donor funding from organizations including TED's Audacious Project, ARPA-H ($27 million), and Google.org
2. Strategic Commercial Partnerships: Once candidates are derisked through preclinical development, Phare partners with large pharma companies for clinical trials, or spins out new companies. The Basilea partnership includes success-based payments for advancing novel antibiotics
3. Company Spin-outs: Phare Bio develops a novel pipeline of AI-optimized antibiotic candidates and builds sustainable clinical paths through company spin-outs for long-term sustainability

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Phare Bio is a nonprofit social venture that uses generative AI and deep learning (the AIBiotics platform, built with the Collins Lab at MIT) to design and develop novel classes of antibiotics against drug-resistant pathogens. The company performs preclinical discovery and development using donor funding and then advances candidates into clinical trials through strategic pharmaceutical partnerships (e.g., Basilea) or company spin-outs. Its immediate customers are pharmaceutical partners and grant/foundation funders, not end patients.

Product overview

Phare Bio is a social venture offering a unified AI-driven antibiotic discovery platform called AIBiotics. The platform integrates generative AI and deep learning capabilities to design novel antibiotics, followed by hit-to-lead optimization (drug metabolism, toxicology, pharmacokinetics, and efficacy assays) and preclinical development (drug delivery and in vivo efficacy profiling). The company addresses the antibiotic development pipeline from initial discovery through preclinical stages, then partners with large pharma companies or spins out new companies for clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• AIBiotics: The world's first generative AI antibiotics discovery engine designed to design and develop novel antibiotics against urgent threats like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.

Products and services

• AIBiotics Generative AI Discovery Platform AIBiotics is Phare Bio's proprietary generative AI and deep learning platform for designing and developing novel antibiotics against drug-resistant pathogens such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. It screens 1000x as many molecules, 5x faster, and at 100x greater success rate than conventional approaches, integrating fragment-based screening with de novo compound generation and feeding downstream hit-to-lead optimization and preclinical development. It is used internally by Phare Bio's science team and, via strategic partnerships and spin-outs, is the technology backbone for advancing candidates into clinical development with pharmaceutical partners.

Quantifiable outcome

• Screens 1000x as many molecules, 5x faster, at 100x greater success rate
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Basilea PharmaceuticalscoreStrategic or Co-development Partner · 14 April 2026Phare Bio and Basilea Pharmaceuticals partnered to develop antimicrobials, leveraging AI to advance molecules from discovery through clinical trials. The collaboration involves CEO Akhila Kosaraju, MD discussing innovation in antibiotic development.
• Basilea PharmaceuticacoreStrategic or Co-development Partner · 11 December 2025Basilea Pharmaceutica and Phare Bio entered a partnership to develop a novel antibiotic using AI-driven molecule design. The collaboration aims to address antimicrobial resistance by combining Basilea's anti-infectives industry expertise with Phare's unique AI capabilities. Phare Bio is eligible for success-based payments.
• Prokaryotics Inc.minorStrategic or Co-development PartnerBasilea announced preclinical partnership with Prokaryotics Inc. for broad-spectrum antifungal development, alongside the Phare Bio partnership for AI-assisted antibiotic discovery.
• MIT Collins LabcoreStrategic or Co-development PartnerCore partnership with James J. Collins' laboratory at MIT for building the first-ever generative AI platform for novel antibiotic discovery. The lab pioneered AI-driven antibiotic discovery including the halicin breakthrough in 2020 and more recently generative AI-designed antibiotics published in Cell 2025.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Recursion Pharmaceuticals: AI-enabled drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutics; a direct competitor to Phare in the AI-for-drug-discovery space with publicly disclosed pipeline assets.
• Insitro: Machine learning-driven drug discovery company using AI/ML platforms to design novel therapeutics — directly comparable to Phare's generative AI approach for antibiotic discovery, though broader in therapeutic scope.
• Iambic Therapeutics: AI-driven drug discovery company using physics-informed machine learning to design novel small-molecule therapeutics; directly comparable in deploying generative AI for small-molecule design with platform-licensing economics.
• Schrödinger: Computational chemistry and physics-based drug design platform widely used by pharma; highly comparable as a software-driven small-molecule discovery peer, with both internal pipeline and platform-licensing economics.
• Absci: AI-powered generative biology platform combining wet-lab and computational methods to design novel antibody therapeutics; comparable platform-based AI drug discovery approach with public-company scale.
• Kinvard Bio: Harvard spin-out developing a novel class of antibacterials; directly comparable as an early-stage anti-infectives discovery company targeting drug-resistant pathogens, with overlapping scientific founders in the AMR space.
• Atomwise: AI-driven small molecule drug discovery company using deep learning to design novel therapeutics; comparable platform approach to Phare with broader therapeutic-area focus.
• ArrePath: AI-enabled antibacterial discovery biotech developing novel antibiotics against drug-resistant pathogens; closely comparable focus area to Phare Bio's anti-infectives mission.
• Generate Biomedicines: Generative AI platform for designing novel protein-based therapeutics; comparable in deploying generative biology at scale to create drug candidates de novo, though focused on biologics rather than small molecules.

Broad incumbents

• Isomorphic Labs: Alphabet/DeepMind's drug discovery spin-out using AlphaFold-derived AI for computational drug design; a well-capitalized incumbent applying similar AI methodology to therapeutic discovery at much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/phare-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phare Bio